James Geib

521 total citations
21 papers, 401 citations indexed

About

James Geib is a scholar working on Genetics, Oncology and Molecular Biology. According to data from OpenAlex, James Geib has authored 21 papers receiving a total of 401 indexed citations (citations by other indexed papers that have themselves been cited), including 7 papers in Genetics, 7 papers in Oncology and 6 papers in Molecular Biology. Recurrent topics in James Geib's work include CAR-T cell therapy research (5 papers), Cancer Immunotherapy and Biomarkers (5 papers) and Hemoglobinopathies and Related Disorders (5 papers). James Geib is often cited by papers focused on CAR-T cell therapy research (5 papers), Cancer Immunotherapy and Biomarkers (5 papers) and Hemoglobinopathies and Related Disorders (5 papers). James Geib collaborates with scholars based in United States, United Kingdom and Italy. James Geib's co-authors include Lawrence C. Kuo, Steven S. Carroll, Mark W. Stahlhut, David B. Olsen, John D. Gehman, Jules A. Shafer, Álvaro Fernández-Quilez, Ben Adeyi, Albert E. Yellin and Mohinder K. Sardana and has published in prestigious journals such as Journal of Biological Chemistry, Journal of Clinical Oncology and Blood.

In The Last Decade

James Geib

21 papers receiving 389 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
James Geib United States 10 112 100 71 70 62 21 401
Lawrence Galitz United States 8 119 1.1× 74 0.7× 149 2.1× 87 1.2× 54 0.9× 12 480
Steve Weller United States 7 27 0.2× 81 0.8× 46 0.6× 87 1.2× 39 0.6× 9 295
Peter van Deursen Netherlands 6 136 1.2× 57 0.6× 131 1.8× 59 0.8× 31 0.5× 6 349
Carol Goulding Ireland 9 22 0.2× 42 0.4× 152 2.1× 36 0.5× 32 0.5× 15 434
Abbe Rubin United States 10 65 0.6× 87 0.9× 62 0.9× 38 0.5× 60 1.0× 13 563
M. Wolf Germany 10 93 0.8× 83 0.8× 175 2.5× 69 1.0× 22 0.4× 23 531
Olga Millán Spain 18 24 0.2× 142 1.4× 159 2.2× 110 1.6× 55 0.9× 46 852
Régine Rouzier‐Panis France 6 15 0.1× 41 0.4× 143 2.0× 77 1.1× 84 1.4× 10 339
Michela Montagna Italy 5 43 0.4× 32 0.3× 28 0.4× 94 1.3× 70 1.1× 8 341
T Koshiba Japan 18 106 0.9× 70 0.7× 209 2.9× 121 1.7× 66 1.1× 61 1.4k

Countries citing papers authored by James Geib

Since Specialization
Citations

This map shows the geographic impact of James Geib's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by James Geib with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites James Geib more than expected).

Fields of papers citing papers by James Geib

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by James Geib. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by James Geib. The network helps show where James Geib may publish in the future.

Co-authorship network of co-authors of James Geib

This figure shows the co-authorship network connecting the top 25 collaborators of James Geib. A scholar is included among the top collaborators of James Geib based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with James Geib. James Geib is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Saraf, Santosh L., Modupe Idowu, Ifeyinwa Osunkwo, et al.. (2024). Multicenter, phase 1 study of etavopivat (FT-4202) treatment for up to 12 weeks in patients with sickle cell disease. Blood Advances. 8(16). 4459–4475. 7 indexed citations
2.
3.
Schroeder, Patricia, James Geib, Diamantis G. Konstantinidis, et al.. (2022). Safety, Pharmacokinetics, and Pharmacodynamics of Etavopivat (FT‐4202), an Allosteric Activator of Pyruvate Kinase‐R, in Healthy Adults: A Randomized, Placebo‐Controlled, Double‐Blind, First‐in‐Human Phase 1 Trial. Clinical Pharmacology in Drug Development. 11(5). 654–665. 23 indexed citations
4.
5.
Wood, Kenneth W., James Geib, Eric Wu, et al.. (2020). An Adaptive, Randomized, Placebo-Controlled, Double-Blind, Multi-Center Study of Oral FT-4202, a Pyruvate Kinase Activator in Patients with Sickle Cell Disease (PRAISE). Blood. 136(Supplement 1). 19–20. 4 indexed citations
6.
Babiker, Hani M., Vivek Subbiah, Orla Maguire, et al.. (2019). Abstract 4062: Activation of innate and adaptive immunity using intratumoral tilsotolimod (IMO-2125) as monotherapy in patients with refractory solid tumors: a phase Ib study (ILLUMINATE-101). Cancer Research. 79(13_Supplement). 4062–4062. 5 indexed citations
7.
Ascierto, Paolo A., Petr Arenberger, Victoria Atkinson, et al.. (2018). ILLUMINATE 301: A randomized phase III comparison of IMO-2125 with ipilimumab (ipi) versus ipi alone in subjects with anti PD 1 refractory melanoma. Annals of Oncology. 29. viii466–viii466. 1 indexed citations
8.
9.
Diab, Adi, Cara Haymaker, Marc Uemura, et al.. (2017). A Phase 1/2 trial of intratumoral (i.t.) IMO-2125 (IMO) in combination with checkpoint inhibitors (CPI) in PD-(L)1-refractory melanoma. Annals of Oncology. 28. v421–v421. 11 indexed citations
10.
Yen, Chung‐Jen, Ezra E.W. Cohen, Jan B. Vermorken, et al.. (2015). 342TiP Phase 3 trial of pembrolizumab as a first-line treatment in subjects with recurrent/metastatic head and neck squamous cell carcinoma: KEYNOTE-048. Annals of Oncology. 26. ix93–ix93. 1 indexed citations
11.
Cohen, Ezra E.W., Jan B. Vermorken, Kevin J. Harrington, et al.. (2015). Phase 3 trial of pembrolizumab as a first-line treatment in subjects with recurrent/metastatic head and neck squamous cell carcinoma: KEYNOTE-048. Annals of Oncology. 26. viii5–viii5. 6 indexed citations
12.
Afdhal, Nezam H., Geoffrey Dusheiko, Edoardo G. Giannini, et al.. (2013). Eltrombopag Increases Platelet Numbers in Thrombocytopenic Patients With HCV Infection and Cirrhosis, Allowing for Effective Antiviral Therapy. Gastroenterology. 146(2). 442–452.e1. 98 indexed citations
13.
Dusheiko, Geoffrey, Nezam H. Afdhal, Edoardo G. Giannini, et al.. (2012). 60 RESULTS OF ENABLE 2, A PHASE 3, MULTICENTER STUDY OF ELTROMBOPAG AND PEGINTERFERON ALFA-2B TREATMENT IN PATIENTS WITH HEPATITIS C AND THROMBOCYTOPENIA. Journal of Hepatology. 56. S27–S27. 4 indexed citations
14.
Afdhal, Nezam H., Geoffrey Dusheiko, Edoardo G. Giannini, et al.. (2011). FINAL RESULTS OF ENABLE 1, A PHASE 3, MULTICENTER STUDY OF ELTROMBOPAG AS AN ADJUNCT FOR ANTIVIRAL TREATMENT OF HEPATITIS C VIRUS-RELATED CHRONIC LIVER DISEASE ASSOCIATED WITH THROMBOCYTOPENIA. UCL Discovery (University College London). 12 indexed citations
15.
Dusheiko, Geoffrey, Nezam H. Afdhal, Edoardo G. Giannini, et al.. (2011). Final Results of Open-Label Treatment with Eltrombopag During ENABLE 1: A Study of Eltrombopag As An Adjunct for Antiviral Treatment of Hepatitis C Virus Associated with Thrombocytopenia. Blood. 118(21). 2232–2232. 4 indexed citations
16.
Yellin, Albert E., James M. Hassett, Álvaro Fernández-Quilez, et al.. (2002). Ertapenem monotherapy versus combination therapy with ceftriaxone plus metronidazole for treatment of complicated intra-abdominal infections in adults. International Journal of Antimicrobial Agents. 20(3). 165–173. 56 indexed citations
17.
Carroll, Steven S., et al.. (1997). Activation of RNase L by 2′,5′-Oligoadenylates. Journal of Biological Chemistry. 272(31). 19193–19198. 22 indexed citations
18.
Carroll, Steven S., Elizabeth Chen, James Geib, et al.. (1996). Cleavage of Oligoribonucleotides by the 2′,5′-Oligoadenylate- dependent Ribonuclease L. Journal of Biological Chemistry. 271(9). 4988–4992. 54 indexed citations
19.
Carroll, Steven S., James Geib, David B. Olsen, et al.. (1994). Sensitivity of HIV-1 Reverse Transcriptase and Its Mutants to Inhibition by Azidothymidine Triphosphate. Biochemistry. 33(8). 2113–2120. 51 indexed citations
20.
Carroll, Steve S., Mark W. Stahlhut, James Geib, & David B. Olsen. (1994). Inhibition of HIV-1 reverse transcriptase by a quinazolinone and comparison with inhibition by pyridinones. Differences in the rates of inhibitor binding and in synergistic inhibition with nucleoside analogs.. Journal of Biological Chemistry. 269(51). 32351–32357. 17 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Lawrence Galitz Breakdown of academic impact, for papers by Steve Weller Breakdown of academic impact, for papers by Peter van Deursen Breakdown of academic impact, for papers by Carol Goulding Breakdown of academic impact, for papers by Abbe Rubin Breakdown of academic impact, for papers by M. Wolf Breakdown of academic impact, for papers by Olga Millán Breakdown of academic impact, for papers by Régine Rouzier‐Panis Breakdown of academic impact, for papers by Michela Montagna Breakdown of academic impact, for papers by T Koshiba
Rankless by CCL
2026